New Market Research Report: Australia Pharmaceuticals & Healthcare Report Q2 2015

The Australian government will continue to use drug price controls as a means to reduce healthcare expenditure. Our view is based on the government's runaway budget deficit and the inevitable increased demand for medicines as the population ages and incidence of long-term diseases rise. Consequently, government price controls will continue to present downside risk to drugmakers selling their products in Australia. The need to curb growing healthcare expenditure and high medicine prices will result in the government targeting medicine prices.

Full Report Details at
- http://www.fastmr.com/prod/977475_australia_pharmaceuticals_healthcare_report_q2.aspx?afid=301

Headline Expenditure Projections

* Pharmaceuticals: AUD12.95bn (USD12.50bn) in 2013 to AUD13.48bn (USD12.40bn) in 2014; +4.0% in local currency terms and -0.8% in US dollar terms, due to significant exchange rate fluctuations. Forecast downgraded after taking into account new data for the Pharmaceutical Benefits Scheme's expenditure.
* Healthcare: AUD142.16bn (USD137.18bn) in 2013 to AUD149.19bn (USD137.35bn) in 2014; +4.9% in local currency terms and 0.1% in US dollar terms, due to exchange rate fluctuations.

Risk/Reward Rating

Australia's Pharmaceutical Risk/Reward Rating (RRR) score for Q115 increased to 67.0 out of the maximum 100 and kept third position within the region. In general, Australia scored above average for all indicators and sub-indicators. However, among the top five countries Australia and Hong Kong have the lowest Industry Rewards scores with 23.6 and 22.4 respectively. Australia's score is boosted by a relatively large pensionable population, a steadily growing population through immigration and high spending per capita second only to Japan, but dragged down by a declining pharmaceutical market.

Key Trends And Developments

October 2014

A report revealed that the Australian health sector is witnessing a gap in the quality of health between the richest, most advantaged and poorest, disadvantaged citizens. The report, which is based on 2011-2013 data from the Australia Bureau of...

The Australia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Australia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Australia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Australia, to test other views - a key input for successful budgeting and strategic business planning in the Australian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015